SFDA Tightens TCM Injection Regulations
This article was originally published in PharmAsia News
China's State Food and Drug Administration recently released the basic technology requirements for traditional Chinese medicine and natural injection to tackle problems in TCM injection such as complicated chemical ingredients, poor preparation technology, shoddy standards, and undeterminate clinical effects. The new regulation requires TCM and natural product injection to identify their ingredients, with single-ingredient TCM injections attaining a purity level of 90 percent. It also seeks to regulate injections with altered route of administration or dosage and better guidelines for generic drugs. Besides imposing more control on non-clinical study and clinical trials, SFDA proposes a surveillance system on adverse drug reactions. Industry observers believe that the stricter regulations will raise TCM production safety and efficacy. (Click here for more
You may also be interested in...
SHANGHAI - China has ordered a recall of two batches of acanthopanax-based injections, also know as Siberian ginseng, after reports of serious adverse reactions that caused the death of three patients in Yunan Province, China's Ministry of Health announced Oct. 11
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.